Top

Published in:

01-04-2010 | Review

Type 1 interferons and myositis

Author: Steven A Greenberg

Published in: Arthritis Research & Therapy | Special Issue 1/2010

Abstract

Recent studies suggest a mechanistic role for molecules induced by type 1 interferons in the pathogenesis of some forms of myositis. For dermatomyositis, evidence that these molecules injure myofibers seems especially strong. In the group of disorders known as polymyositis, the study of blood samples suggests a potential role. It is unknown what drives the sustained presence of type 1 interferon-inducible molecules in these diseases, as the type 1 interferons themselves have not been specifically detected along with their downstream biomarkers. Therapeutic development for blockade of IFNα is in progress aided by the identification of blood genomic biomarkers.

Greenberg SA: Inflammatory myopathies: disease mechanisms. Curr Opin Neurol. 2009, 22: 516-523. 10.1097/WCO.0b013e3283311ddf.CrossRefPubMed

Salajegheh M, Kong SW, Pinkus JL, Walsh RJ, Liao A, Nazareno R, Amato AA, Krastins B, Morehouse C, Higgs BW, Jallal B, Yao Y, Sarracino DA, Parker KC, Greenberg SA: Interferon-stimulated gene 15 (ISG15) conjugates proteins in dermatomyositis muscle with perifascicular atrophy. Ann Neurol. 2009, 67: 53-63. 10.1002/ana.21805.CrossRef

Greenberg SA: Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications. Neurology. 2007, 69: 2008-2019. 10.1212/01.WNL.0000291619.17160.b8.CrossRefPubMed

Isenberg DA, Rowe D, Shearer M, Novick D, Beverley PC: Localization of interferons and interleukin 2 in polymyositis and muscular dystrophy. Clin Exp Immunol. 1986, 63: 450-458.PubMedCentralPubMed

Emslie-Smith AM, Arahata K, Engel AG: Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies. Hum Pathol. 1989, 20: 224-231. 10.1016/0046-8177(89)90128-7.CrossRefPubMed

Lundberg I, Brengman JM, Engel AG: Analysis of cytokine expression in muscle in inflammatory myopathies, Duchenne dystrophy, and non-weak controls. J Neuroimmunol. 1995, 63: 9-16. 10.1016/0165-5728(95)00122-0.CrossRefPubMed

Figarella-Branger D, Civatte M, Bartoli C, Pellissier JF: Cytokines, chemokines, and cell adhesion molecules in inflammatory myopathies. Muscle Nerve. 2003, 28: 659-682. 10.1002/mus.10462.CrossRefPubMed

Salomonsson S, Lundberg IE: Cytokines in idiopathic inflammatory myopathies. Autoimmunity. 2006, 39: 177-190. 10.1080/08916930600622256.CrossRefPubMed

Schmidt J, Barthel K, Wrede A, Salajegheh M, Bahr M, Dalakas MC: Interrelation of inflammation and APP in sIBM: IL-1 beta induces accumulation of beta-amyloid in skeletal muscle. Brain. 2008, 131 (Pt 5): 1228-1240.PubMedCentralPubMed

10.

Banker BQ: Dermatomyostis of childhood, ultrastructural alteratious of muscle and intramuscular blood vessels. J Neuropathol Exp Neurol. 1975, 34: 46-75. 10.1097/00005072-197501000-00005.CrossRefPubMed

11.

Norton WL, Velayos E, Robison L: Endothelial inclusions in dermatomyositis. Ann Rheum Dis. 1970, 29: 67-72. 10.1136/ard.29.1.67.PubMedCentralCrossRefPubMed

12.

Grimley PM, Davis GL, Kang YH, Dooley JS, Strohmaier J, Hoofnagle JH: Tubuloreticular inclusions in peripheral blood mononuclear cells related to systemic therapy with alpha-interferon. Lab Invest. 1985, 52: 638-649.PubMed

13.

Rich SA, Owens TR, Bartholomew LE, Gutterman JU: Immune interferon does not stimulate formation of alpha and beta interferon induced human lupus-type inclusions. Lancet. 1983, 1: 127-128. 10.1016/S0140-6736(83)91771-3.CrossRefPubMed

14.

Grimley PM, Rutherford MN, Kang YH, Williams T, Woody JN, Silverman RH: Formation of tubuloreticular inclusions in human lymphoma cells compared to the induction of 2'-5'-oligoadenylate synthetase by leucocyte interferon in dose-effect and kinetic studies. Cancer Res. 1984, 44: 3480-3488.PubMed

15.

Kuyama J, Kanayama Y, Mizutani H, Katagiri S, Tamaki T, Yonezawa T, Tarui S, Morise H, Arimura H, Suyama T: Formation of tubuloreticular inclusions in mitogen-stimulated human lymphocyte cultures by endogenous or exogenous alpha-interferon. Ultrastruct Pathol. 1986, 10: 77-85. 10.3109/01913128609015565.CrossRefPubMed

16.

Feldman D, Goldstein AL, Cox DC, Grimley PM: Cultured human endothelial cells treated with recombinant leukocyte A interferon. Tubuloreticular inclusion formation, antiproliferative effect, and 2',5' oligoadenylate synthetase induction. Lab Invest. 1988, 58: 584-589.PubMed

17.

Greenberg SA, Amato AA: Uncertainties in the pathogenesis of adult dermatomyositis. Curr Opin Neurol. 2004, 17: 359-364. 10.1097/00019052-200406000-00018.CrossRefPubMed

18.

Greenberg SA, Pinkus JL, Pinkus GS, Burleson T, Sanoudou D, Tawil R, Barohn RJ, Saperstein DS, Briemberg HR, Ericsson M, Park P, Amato AA: Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol. 2005, 57: 664-678. 10.1002/ana.20464.CrossRefPubMed

19.

Walsh RJ, Kong SW, Yao Y, Jallal B, Kiener PA, Pinkus JL, Beggs AH, Amato AA, Greenberg SA: Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum. 2007, 56: 3784-3792. 10.1002/art.22928.PubMedCentralCrossRefPubMed

20.

Kea B, Pesich R, Chung LS, Brown PO, Fiorentino D: Genomic analyses identify lipid metabolism abnormalities in dermatomyositis patients [abstract]. J Invest Dermatol. 2007, 127 (Suppl 1): S12-

21.

Greenberg SA, Fiorentino D: Similar topology of injury to keratinocytes and myofibres in dermatomyositis skin and muscle. Br J Dermatol. 2009, 160: 464-465. 10.1111/j.1365-2133.2008.08967.x.CrossRefPubMed

22.

Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Fujita T, Kuwana M: RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum. 2009, 60: 2193-2200. 10.1002/art.24621.CrossRefPubMed

23.

Baechler EC, Bauer JW, Slattery CA, Ortmann WA, Espe KJ, Novitzke J, Ytterberg SR, Gregersen PK, Behrens TW, Reed AM: An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med. 2007, 13: 59-68. 10.2119/2006-00085.Baechler.PubMedCentralCrossRefPubMed

24.

Hooks JJ, Jordan GW, Cupps T, Moutsopoulos HM, Fauci AS, Notkins AL: Multiple interferons in the circulation of patients with systemic lupus erythematosus and vasculitis. Arthritis Rheum. 1982, 25: 396-400. 10.1002/art.1780250406.CrossRefPubMed

25.

Hooks JJ, Moutsopoulos HM, Geis SA, Stahl NI, Decker JL, Notkins AL: Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med. 1979, 301: 5-8. 10.1056/NEJM197907053010102.CrossRefPubMed

26.

Preble OT, Black RJ, Friedman RM, Klippel JH, Vilcek J: Systemic lupus erythematosus: presence in human serum of an unusual acid-labile leukocyte interferon. Science. 1982, 216: 429-431. 10.1126/science.6176024.CrossRefPubMed

27.

Ytterberg SR, Schnitzer TJ: Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum. 1982, 25: 401-406. 10.1002/art.1780250407.CrossRefPubMed

28.

Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, Shark KB, Grande WJ, Hughes KM, Kapur V, Gregersen PK, Behrens TW: Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA. 2003, 100: 2610-2615. 10.1073/pnas.0337679100.PubMedCentralCrossRefPubMed

29.

Hua J, Kirou K, Lee C, Crow MK: Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum. 2006, 54: 1906-1916. 10.1002/art.21890.CrossRefPubMed

30.

Sato M, Suemori H, Hata N, Asagiri M, Ogasawara K, Nakao K, Nakaya T, Katsuki M, Noguchi S, Tanaka N, Taniguchi T: Distinct and essential roles of transcription factors IRF-3 and IRF-7 in response to viruses for IFN-alpha/beta gene induction. Immunity. 2000, 13: 539-548. 10.1016/S1074-7613(00)00053-4.CrossRefPubMed

31.

Sato M, Tanaka N, Hata N, Oda E, Taniguchi T: Involvement of the IRF family transcription factor IRF-3 in virus-induced activation of the IFN-beta gene. FEBS Lett. 1998, 425: 112-116. 10.1016/S0014-5793(98)00210-5.CrossRefPubMed

32.

Marie I, Durbin JE, Levy DE: Differential viral induction of distinct interferonalpha genes by positive feedback through interferon regulatory factor-7. Embo J. 1998, 17: 6660-6669. 10.1093/emboj/17.22.6660.PubMedCentralCrossRefPubMed

33.

Sato M, Hata N, Asagiri M, Nakaya T, Taniguchi T, Tanaka N: Positive feedback regulation of type I IFN genes by the IFN-inducible transcription factor IRF-7. FEBS Lett. 1998, 441: 106-110. 10.1016/S0014-5793(98)01514-2.CrossRefPubMed

34.

Niewold TB, Kariuki SN, Morgan GA, Shrestha S, Pachman LM: Elevated serum interferon-alpha activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after thirty-six months of therapy. Arthritis Rheum. 2009, 60: 1815-1824. 10.1002/art.24555.PubMedCentralCrossRefPubMed

35.

Palucka AK, Blanck JP, Bennett L, Pascual V, Banchereau J: Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci USA. 2005, 102: 3372-3377. 10.1073/pnas.0408506102.PubMedCentralCrossRefPubMed

36.

Mavragani CP, Niewold TB, Moutsopoulos NM, Pillemer SR, Wahl SM, Crow MK: Augmented interferon-alpha pathway activation in patients with Sjogren's syndrome treated with etanercept. Arthritis Rheum. 2007, 56: 3995-4004. 10.1002/art.23062.PubMedCentralCrossRefPubMed

37.

Hengstman GJ, De Bleecker JL, Feist E, Vissing J, Denton CP, Manoussakis MN, Slott Jensen H, van Engelen BG, Hoogen van den FH: Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate. Eur Neurol. 2008, 59: 159-163. 10.1159/000114036.CrossRefPubMed

38.

Dastmalchi M, Grundtman C, Alexanderson H, Mavragani CP, Einarsdottir H, Helmers SB, Elvin K, Crow MK, Nennesmo I, Lundberg IE: A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis. 2008, 67: 1670-1677. 10.1136/ard.2007.077974.CrossRefPubMed

39.

A study to evaluate safety of multi-dose MEDI-545 in adult patients with dermatomyositis or polymyositis. [http://clinicaltrials.gov/ct2/show/NCT00533091]

Title: Type 1 interferons and myositis
Author: Steven A Greenberg
Publication date: 01-04-2010
Publisher: BioMed Central
Published in: Arthritis Research & Therapy / Issue Special Issue 1/2010
Electronic ISSN: 1478-6362
DOI: https://doi.org/10.1186/ar2885

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Type 1 interferons and myositis

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Special Issue 1/2010

Potential role of IFNα in adult lupus

Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNα antibody, in systemic lupus erythematosus

Genetic associations in type I interferon related pathways with autoimmunity

Type I interferon in organ-targeted autoimmune and inflammatory diseases

Overview of the biology of type I interferons

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page